Next Article in Journal
High-Affinity Antibodies Designing of SARS-CoV-2 Based on Molecular Dynamics Simulations
Next Article in Special Issue
CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
Previous Article in Journal
Overexpression of ZmDHN15 Enhances Cold Tolerance in Yeast and Arabidopsis
Previous Article in Special Issue
Tumor Suppressor miRNA-503 Inhibits Cell Invasion in Head and Neck Cancer through the Wnt Signaling Pathway via the WNT3A/MMP Molecular Axis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 1
10.3390/ijms24010478
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Therapeutic Perspectives of HIV-Associated Chemokine Receptor (CCR5 and CXCR4) Antagonists in Carcinomas

by
Wilfredo Alejandro González-Arriagada
1,2,3,*,
Isaac E. García
4,5,6,
René Martínez-Flores
7,
Sebastián Morales-Pison
8 and
Ricardo D. Coletta
9
1
Facultad de Odontología, Universidad de Los Andes, Santiago 7620086, Chile
2
Centro de Investigación e Innovación Biomédica (CIIB), Universidad de los Andes, Santiago 7620086, Chile
3
Patología Oral y Maxilofacial, Hospital El Carmen Luis Valentín Ferrada, Maipú 9251521, Chile
4
Laboratorio de Fisiología y Biofísica, Facultad de Odontología, Universidad de Valparaíso, Valparaíso 2360004, Chile
5
Centro de Investigación en Ciencias Odontológicas y Médicas, Universidad de Valparaíso, Valparaíso 2360004, Chile
6
Centro Interdisciplinario de Neurociencias de Valparaíso, Universidad de Valparaíso, Valparaíso 2381850, Chile
7
Unidad de Patología y Medicina Oral, Facultad de Odontología, Universidad Andres Bello, Viña del Mar 2531015, Chile
8
Centro de Oncología de Precisión (COP), Facultad de Medicina y Ciencias de la Salud, Universidad Mayor, Santiago 7560908, Chile
9
Department of Oral Diagnosis and Graduate Program in Oral Biology, Piracicaba Dental School, University of Campinas, Piracicaba 13414-903, SP, Brazil
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(1), 478; https://doi.org/10.3390/ijms24010478
Submission received: 8 November 2022 / Revised: 22 December 2022 / Accepted: 23 December 2022 / Published: 28 December 2022
(This article belongs to the Special Issue Novel Therapeutic Targets in Cancers)
Browse Figures
Review Reports Versions Notes

Abstract

:
The interaction between malignant cells and the tumor microenvironment is critical for tumor progression, and the chemokine ligand/receptor axes play a crucial role in this process. The CXCR4/CXCL12 and CCR5/CCL5 axes, both related to HIV, have been associated with the early (epithelial–mesenchymal transition and invasion) and late events (migration and metastasis) of cancer progression. In addition, these axes can also modulate the immune response against tumors. Thus, antagonists against the receptors of these axes have been proposed in cancer therapy. Although preclinical studies have shown promising results, clinical trials are needed to include these drugs in the oncological treatment protocols. New alternatives for these antagonists, such as dual CXCR4/CCR5 antagonists or combined therapy in association with immunotherapy, need to be studied in cancer therapy.

1. Introduction

Cancer involves multiple events, such as uncontrolled proliferation and DNA repair failures, that trigger genetic instability, invasion, migration, angiogenesis, and metastasis. These later events depend on the interactions between malignant cells and many cells belonging to the tumor microenvironment, leading to tumor progression [1]. These processes require the activation or inhibition of different cell signaling pathways mediated by cell surface receptors and their ligands for which the chemokine ligand/receptor axes play key roles [2]. According to their chemical structure, chemokines comprise four subtypes of cytokines (C, CC, CXC, and CX3C) that act as the ligand on one or more receptors. On the other hand, chemokine receptors CR, CCR, CXCR, and CX3CR are G protein-coupled receptors activated for one or more subtypes of chemokines [3].
In cancer, and other diseases, a chemokine receptor may activate a proinflammatory or anti-inflammatory pathway, a duality exploited by neoplastic cells to improve the capacity to (i) evade the immune system, (ii) degrade the extracellular matrix, and (iii) invade the neural or vascular compartment producing metastasis [3,4]. In this sense, our great interest is the role of CXCR4/CXCL12 and CCR5/CCL5 axes in the pathogenesis of epithelial malignancies, including lung [5], gastric [6], pancreatic [7], colorectal [8], breast [9], ovarian [10], prostatic [4], hepatocellular [11], and head and neck carcinomas [12,13], as well as adenocarcinomas [14] and non-epithelial cancers such as melanoma [15], multiple myeloma [16], and lymphomas [17].
Preclinical investigations (in vitro and in vivo) have proved the efficacy of HIV-related chemokine receptor (HIVrCR) antagonists for cancer treatment. Chemokine receptor antagonist (CRA) drugs such as maraviroc (CCR5 antagonist) or plerixafor (CXCR4 antagonist) have shown a role in the suppression of cancer cell proliferation, migration, and metastasis [18,19]. Thus, the CRA-promoted blockade of these axes arises as an alternative or complementary therapy to improve outcomes in tumors resistant to radiotherapy and chemotherapy in carcinomas [11,20,21,22,23,24,25]. In this context, we aim to conduct a scoping review of the literature to describe the results of promising CRA therapies for carcinomas in order to identify the drugs to be used in the future.

2. Materials and Methods

This study followed the PRISMA extensions for Scoping Reviews.

2.1. Inclusion and Exclusion Criteria

Eligibility criteria included the articles related to CRA therapy and carcinoma published from 2010 to September 2022 in English. Clinical trials and in vitro and in vivo studies were included. Exclusion criteria were articles that do not study the role of CCR antagonists as therapy, with a focus on other drugs, with other study designs, other publication types, and with a focus on other malignancies (sarcoma or lymphoproliferative). Unpublished clinical trials were not included.

2.2. Search Strategy

An electronic search was performed in the following databases: PubMed/Medline, Web of Science, and Scopus. The search terms were “chemokine receptor”, “CXCR4”, “CCR5” and “cancer therapy”.
PubMed/Medline: (“chemokine”(All Fields) AND “receptor”(All Fields)) OR (“chemokine receptor”(All Fields) OR “CXCR4”(All Fields) OR “CCR5”(All Fields)) AND (“cancer”(All Fields) AND “therapy”(All Fields)) OR (“cancer therapy”(All Fields)).
Web of Science: (((ALL = (chemokine receptor)) OR ALL = (CXCR4)) OR (ALL = (CCR5) AND ALL = (cancer therapy)).
Scopus: ABS (chemokine AND receptor OR cxcr4 OR ccr5 AND cancer AND therapy).
The references of the included studies and the relevant reviews were checked for possible further studies.

2.3. Study Selection

The title and abstract of all the articles were identified and selected using the web tool Rayyan (https://www.rayyan.ai/, accessed on 14 October 2022). The abstracts were read independently by the authors. Controversies were resolved by discussion between the authors.

2.4. Data Extraction

Data were tabulated using a specially designed form in Microsoft Excel®. The following data were extracted: author, country, year of publication, study design (three categories: clinical trial, in vitro and in vivo studies), receptor, antagonist, adjuvant therapy, type of cancer, oncogenic mechanisms involved, effective doses in vitro, effective doses in vivo, metastasis in vivo, survival in vivo and primary tumor size in vivo.

2.5. Data Analysis

A qualitative synthesis of the extracted data was performed through the resume table.

3. Results

3.1. Study Selection

A flowchart describing the selection process is presented in Figure 1. The search strategy returned 3807 articles published between 2010 and 2022 in all the databases. Duplicate records (1853 articles) were excluded, and 1954 remained for screening. After screening by title and abstract, the 150 remaining studies were assessed for eligibility with the full text. Finally, 89 articles were excluded based on the reasons detailed in Figure 1, and 61 publications were included (53 preclinical studies and 8 clinical trials).

3.2. Description of Preclinical Studies

Supplementary Table S1 summarizes a qualitative synthesis of the preclinical studies. Forty-three publications reported CXCR4 antagonists, and ten reported CCR5 antagonists.
We found different inhibitors reported, AMD3100 (plerixafor) and maraviroc, the most frequent for CXCR4, and CCR5, respectively. Most studies included in vitro (16 studies) and in vivo (3 studies) methodologies.
Twenty-eight studies included adjuvant therapy. Among these therapies, the most reported were doxorubicin, gemcitabine, paclitaxel, and radiation. Breast cancer was the most common epithelial cancer included. The main oncogenic mechanisms these drugs interfered with were cell invasion, migration, and metastasis. However, the modulation of the immune response is another attractive action pathway of these drugs.

3.3. Description of Clinical Trials

A qualitative synthesis of the published clinical trials is summarized in Supplementary Table S2. All the papers were written in English and published between 2014 and 2022. Seven clinical trials reported CXCR4 antagonists (LY2510924, BL-8040, and mavorixafor), and two clinical trials were reported with a CCR5 antagonist (maraviroc). Three studies reported their results as monotherapy, and six studies used adjuvant therapy of durvalumab, pembrolizumab, nivolumab, sunitinib, and chemotherapy (leucovorin, liposomal irinotecan, and fluorouracil). The most reported inhibitor of CXCR4 was LY2510924, with a dose of 20 mg/day reported in different protocols. The inhibitor of CCR5, maraviroc, was used at 300 mg twice daily for two months. Other reported inhibitors of CXCR4 were motixafortide and mavorixafor. All the studies reported favorable survival results.

4. Discussion

The present review describes the current therapeutical perspectives of HIVrCR, CCR5, and CXCR4 antagonist drugs in treating carcinomas. Chemokines are associated with leukocyte chemoattraction to lymph nodes for maturation. However, cell migration of malignant keratinocytes, leukocytes, endothelial cells, mesenchymal stem cells (MSCs), and cancer-associated fibroblasts (CAFs) arise because of the aberrant expression of chemokine receptors on the surface of cancer cells [26]. Muller et al. were the first to demonstrate that the CXCR4/CXCL12 axis has a role in tumor progression and metastasis in breast cancer [27]. The interaction between cancer cells and the factors released by the microenvironment components is crucial for epithelial cancer progression, playing a role in the early and late events of cancer progression. The migration to lymph stimulated by oncochemoattractant depends on CCR5/CCL5 and CXCR4/CXCL12 axes [12]. The implantation of metastatic islands in lymph nodes requires the preparation of a premetastatic niche, a phenomenon related to the release of CCL5 and CXCL12 by the resident cells of lymph nodes [28,29]. CCL5 and CXCL12 have been linked to cancer progression, epithelial–mesenchymal transition, immune evasion, metastasis, and worse prognosis. Therefore, using antagonists such as small molecules (e.g., maraviroc or Vicriviroc), peptide antagonists, or antibodies have been suggested as therapeutic alternatives [26,30]. The small molecules have been tested in some clinical trials for carcinomas or other inflammatory diseases and are approved for HIV patients. Even if many chemokine receptors were essential for cancer progression, available drugs against HIVrCR have shown promissory results. Additionally, because these receptors are expressed in cancer and defensive cells, these inhibitors could halt cancer progression and modulate the immune response.

4.1. CXCR4/CXCL12 Axis

In normal tissues, this axis is important in developmental processes, hematopoiesis, and inflammation [31] and is expressed in leukocytes, stromal fibroblasts, and endothelial cells [32]. CXC chemokine receptor 4 (CXCR4) is a G-protein-coupled receptor highly expressed in different human carcinomas [4,6,7,8,11,13,29], at all stages of the epithelial–mesenchymal transition, invasion, or metastasis [33], and has been related to a poor prognosis. Leukocytes and CAFs are sources of CXCL12 [34], a chemokine that binds to CXCR4, forming the CXCL12/CXCR4 axis. This axis has a role in different tumor pathways involved in processes such as the epithelial–mesenchymal transition, cell migration, and metastasis, including drug resistance [35,36,37].
Small molecules, such as AMD3100 (plerixafor), WZ811, LFC131, AMD070, LY2510924, X4-136, BPRCX807, and others [19,38,39,40,41,42,43,44,45,46,47,48,49,50], have been reported to inhibit CXCR4, individually or in association with other drugs or therapies (doxorubicin, cisplatin, radiation, and others) [19,40,41,48,49,50,51,52], including different carriers for a better efficacy [10,33,52,53,54,55]. Preclinical studies have shown, both in vitro and in vivo, that the inhibition of CXCR4 is effective in treating cell proliferation, angiogenesis, tumor growth, and the metastasis of different carcinoma cells [19,25,38,39,40,41,42,43,44,51,52,53,54,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76], and it has been reported that CXCR4 blockade increases tumor-infiltrating lymphocytes (TILs) [77]. These drugs modify cell migration and invasion and reduce metastasis [38,40,41,54]. Additionally, they have also been demonstrated to enhance the sensitivity to chemotherapy or radiotherapy, increasing the reduction in cell viability, apoptosis, tumor growth, and metastasis, including the modulation of the crosstalk between tumor and stromal cells [19,40,41,51,52,55,78]. Finally, plerixafor can induce a better immune response against the tumor through the suppression of Treg cells and the regulation of T cell activity [37,59], and recent studies have reported that CXCR4 inhibition enhances the response to immunotherapy [50,79]. Clinical trials have provided interesting data to consider CXCR4 antagonists as an alternative in cancer therapy in multicenter, randomized, and even phase II studies. Using these drugs as coadjuvant therapy has been successful, showing acceptable safety and tolerability in patients with advanced refractory tumors and expanding the benefits of chemotherapy or immunotherapy [47,80,81,82].

4.2. CCR5/CCL5 Axis

The use of CCR5-inhibitor drugs in HIV patients is well tolerated, and diverse clinical outcomes have been observed as monotherapy or combined with other antiretroviral drugs (highly active antiretroviral therapy; HAART). The association of CCR5 with cancer progression is unveiling a new perspective on the use of these drugs.
CC chemokine receptor 5 (CCR5) is a G-protein-coupled receptor reported in different kinds of carcinomas, with the primary role in the late events of cancer progression, such as metastasis [13,18]. CCL3 and CCL5 are the main chemokines that bind to CCR5, forming the CCL3/CCR5 and CCL5/CCR5 activation axes. These chemokines are mainly involved in inflammation, promoting the recruitment of leukocytes to injury sites [26]. The CCR5/CCL5 axis has protumor effects, and the low expression of these proteins can lead to a better prognosis [83].
In carcinomas, some authors have described the relationship between high levels of CCL5 or CCR5 expression in tumors and advanced stages [12,13,84,85,86], including a proangiogenic role [87] and the stimulation of cancer stem cells [88]. Regarding immune modulation, CCL5 can differentiate leukocytes to a protumorigenic profile [89] and can inhibit the antitumorigenic role of CD8+ lymphocytes [90] but can also modulate the activation of Tregs [18] and myeloid-derived suppressor cells [91]. CCL5 was reported as an inducer of cell migration and invasion [92], leading to metastasis [93]. The aggressiveness of CCL5-releasing tumors relies on the fact that they are more aggressive because CCL5 promotes invasion, migration, and metastasis in CCR5-high-expressing tumors.
CCR5 inhibition has demonstrated promising results in controlling cancer development and progression in preclinical studies [18,20,22,93,94,95,96,97]. Maraviroc is a specific small-molecule antagonist of the CCR5 used in preclinical and clinical cancer studies. CCR5 inhibitors were tested to treat liver, pancreatic, and breast cancer cells, showing apoptosis induction, reduced cell invasion and metastasis, and increased survival [20,93,98]. In addition, some studies reported that CCR5 inhibition could modulate the immune response, diminishing Treg infiltration [99,100].
It was reported that the inhibition of CCR5 in colorectal cancer cells, as a single agent, can inhibit proliferation and migration but failed to inhibit metastasis in vivo [101]. However, a study reported that maraviroc could inhibit metastasis in an animal model of colorectal cancer. These contradictory results are probably related to the promiscuity of chemokine receptors and chemokines, suggesting that drugs with dual or multiple inhibitions, or combined therapies (immunotherapy or chemotherapy), could have a better effect against cancer progression and metastasis. Recent preclinical studies have reported that the combination of CCR5 antagonists with anti-PD-L1 can inhibit tumor growth and enhance the therapy outcome in several types of cancer [100,102]. A few reported clinical trials are using CCR5 antagonists [103]. They are in phase I and use maraviroc.

4.3. New Perspectives

These chemokine axes play essential roles in cell migration and metastasis but can also modulate the immune response against tumors (Figure 2). Thus, studies about these axes as therapeutic targets are promising. The development of dual-inhibition drugs for CXCR4 and CCR5, and their association with immunotherapy, are the two main challenges in recent times. Therapies targeting CXCR4 and CCR5 have been reported as probable effective strategies for cancer. AMD3451 is the first reported dual CXCR4/CCR5 antagonist [104], but studies testing these drugs are necessary. Other drugs have also demonstrated a dual effect (e.g., NF279, penicillixanthone A, and GUT-70 [105]). The efficacy of these dual-inhibition drugs is still unknown in cancer.
A few reported clinical trials are testing these drugs in cancer, mainly in association with other therapies [45,46,47,106,107,108], and the results are still confusing. Hainsworth et al. reported a well-documented clinical trial with LY2510924 (anti-CXCR4) associated with sunitinib in metastatic renal cell carcinoma, showing promising results for this novel therapy [46]. On the other hand, clinical trials with maraviroc (antagonist of CCR5) and plerixafor (antagonist of CXCR4) have been reported, either as monotherapy or in combination with other drugs, but the literature mainly shows preclinical results in vitro or in vivo. Recent studies suggest that the chemokine receptor–ligand axis can modulate the tumor immune microenvironment [79]. Moreover, combining CXCR4 or CCR5 antagonists with anti-PD1 immunotherapy has shown promising results in colorectal cancer, renal cell carcinoma, and pancreatic ductal adenocarcinoma, including clinical trials [77,103,104,105,106,108]. These results reveal new alternatives to this therapy for human carcinomas.

5. Conclusions

The HIV-associated chemokine receptor (CCR5 and CXCR4) antagonists have critical roles in inhibiting cell migration, invasion, and metastasis and can modulate the tumoral immune response through Treg regulation. Preclinical studies are promising, but more clinical trials are needed. Future studies are required to test the efficacy of dual CXCR4/CCR5 antagonists and their association with immunotherapy.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms24010478/s1, Table S1: Description of preclinical studies; Table S2: Description of clinical trials.

Author Contributions

Review, W.A.G.-A. and R.M.-F.; writing—review and editing, W.A.G.-A., I.E.G., R.M.-F., S.M.-P. and R.D.C. All authors have read and agreed to the published version of the manuscript.

Funding

This paper was funded by Fondecyt Regular number 1190775 and Fondecyt Iniciación 11180531 from Chilean National Agency for Research and Development.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The authors would like to thank Elena González Cantarutti and José Ignacio García Palacios for their valuable comments and permanent support.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Hanahan, D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022, 12, 31–46. [Google Scholar] [CrossRef] [PubMed]
  2. Raza, S.; Rajak, S.; Tewari, A.; Gupta, P.; Chattopadhyay, N.; Sinha, R.A.; Chakravarti, B. Multifaceted role of chemokines in solid tumors: From biology to therapy. Semin. Cancer Biol. 2022, 86, 1105–1121. [Google Scholar] [CrossRef] [PubMed]
  3. Korbecki, J.; Grochans, S.; Gutowska, I.; Barczak, K.; Baranowska-Bosiacka, I. CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands. Int. J. Mol. Sci. 2020, 21, 7619. [Google Scholar] [CrossRef] [PubMed]
  4. Parol-Kulczyk, M.; Gzil, A.; Ligmanowska, J.; Grzanka, D. Prognostic significance of SDF-1 chemokine and its receptors CXCR4 and CXCR7 involved in EMT of prostate cancer. Cytokine 2022, 150, 155778. [Google Scholar] [CrossRef] [PubMed]
  5. Wang, Y.; Lan, W.; Xu, M.; Song, J.; Mao, J.; Li, C.; Du, X.; Jiang, Y.; Li, E.; Zhang, R.; et al. Cancer-associated fibroblast-derived SDF-1 induces epithelial-mesenchymal transition of lung adenocarcinoma via CXCR4/beta-catenin/PPARdelta signalling. Cell Death Dis. 2021, 12, 214. [Google Scholar] [CrossRef]
  6. Perrot-Applanat, M.; Vacher, S.; Pimpie, C.; Chemlali, W.; Derieux, S.; Pocard, M.; Bieche, I. Differential gene expression in growth factors, epithelial mesenchymal transition and chemotaxis in the diffuse type compared with the intestinal type of gastric cancer. Oncol. Lett. 2019, 18, 674–686. [Google Scholar] [CrossRef] [Green Version]
  7. Singh, S.K.; Mishra, M.K.; Eltoum, I.A.; Bae, S.; Lillard, J.W., Jr.; Singh, R. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Sci. Rep. 2018, 8, 1323. [Google Scholar] [CrossRef] [Green Version]
  8. Ucuncu, M.; Serilmez, M.; Sari, M.; Bademler, S.; Karabulut, S. The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer. Biomolecules 2019, 9, 464. [Google Scholar] [CrossRef] [Green Version]
  9. Dayer, R.; Babashah, S.; Jamshidi, S.; Sadeghizadeh, M. Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis ininvasive breast carcinoma: A potent biomarker predicting lymph node metastasis. J. Cancer Res. Ther. 2018, 14, 345–350. [Google Scholar]
  10. Xue, J.; Li, R.; Gao, D.; Chen, F.; Xie, H. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer. Int. J. Nanomed. 2020, 15, 5701–5718. [Google Scholar] [CrossRef]
  11. Singh, S.K.; Mishra, M.K.; Rivers, B.M.; Gordetsky, J.B.; Bae, S.; Singh, R. Biological and Clinical Significance of the CCR5/CCL5 Axis in Hepatocellular Carcinoma. Cancers 2020, 12, 883. [Google Scholar] [CrossRef] [PubMed]
  12. Domingueti, C.B.; Janini, J.B.; Paranaiba, L.M.; Lozano-Burgos, C.; Olivero, P.; Gonzalez-Arriagada, W.A. Prognostic value of immunoexpression of CCR4, CCR5, CCR7 and CXCR4 in squamous cell carcinoma of tongue and floor of the mouth. Med. Oral Patol. Oral Cir. Bucal 2019, 24, e354–e363. [Google Scholar] [CrossRef] [PubMed]
  13. Gonzalez-Arriagada, W.A.; Lozano-Burgos, C.; Zuniga-Moreta, R.; Gonzalez-Diaz, P.; Coletta, R.D. Clinicopathological significance of chemokine receptor (CCR1, CCR3, CCR4, CCR5, CCR7 and CXCR4) expression in head and neck squamous cell carcinomas. J. Oral Pathol. Med. 2018, 47, 755–763. [Google Scholar] [CrossRef] [PubMed]
  14. Gao, T.; Shen, Z.; Ma, C.; Li, Y.; Kang, X.; Sun, M. The CCL5/CCR5 Chemotactic Pathway Promotes Perineural Invasion in Salivary Adenoid Cystic Carcinoma. J. Oral Maxillofac. Surg. 2018, 76, 1708–1718. [Google Scholar] [CrossRef] [Green Version]
  15. McConnell, A.T.; Ellis, R.; Pathy, B.; Plummer, R.; Lovat, P.E.; O’Boyle, G. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma. Br. J. Dermatol. 2016, 175, 1210–1220. [Google Scholar] [CrossRef] [Green Version]
  16. Beider, K.; Bitner, H.; Leiba, M.; Gutwein, O.; Koren-Michowitz, M.; Ostrovsky, O.; Abraham, M.; Wald, H.; Galun, E.; Peled, A.; et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget 2014, 5, 11283–11296. [Google Scholar] [CrossRef] [Green Version]
  17. Pansy, K.; Feichtinger, J.; Ehall, B.; Uhl, B.; Sedej, M.; Roula, D.; Pursche, B.; Wolf, A.; Zoidl, M.; Steinbauer, E.; et al. The CXCR4-CXCL12-Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro. Int. J. Mol. Sci. 2019, 20, 4740. [Google Scholar] [CrossRef] [Green Version]
  18. Halvorsen, E.C.; Hamilton, M.J.; Young, A.; Wadsworth, B.J.; LePard, N.E.; Lee, H.N.; Firmino, N.; Collier, J.L.; Bennewith, K.L. Maraviroc decreases CCL8-mediated migration of CCR5+ regulatory T cells and reduces metastatic tumor growth in the lungs. OncoImmunology 2016, 5, e1150398. [Google Scholar] [CrossRef] [Green Version]
  19. Chaudary, N.; Pintilie, M.; Jelveh, S.; Lindsay, P.; Hill, R.P.; Milosevic, M. Plerixafor Improves Primary Tumor Response and Reduces Metastases in Cervical Cancer Treated with Radio-Chemotherapy. Clin. Cancer Res. 2017, 23, 1242–1249. [Google Scholar] [CrossRef] [Green Version]
  20. Pervaiz, A.; Zepp, M.; Georges, R.; Bergmann, F.; Mahmood, S.; Faiza, S.; Berger, M.R.; Adwan, H. Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis. J. Cancer Res. Clin. Oncol. 2021, 147, 73–91. [Google Scholar] [CrossRef]
  21. Huang, H.; Zepp, M.; Georges, R.B.; Jarahian, M.; Kazemi, M.; Eyol, E.; Berger, M.R. The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction. Cancer Lett. 2020, 474, 82–93. [Google Scholar] [CrossRef] [PubMed]
  22. Pervaiz, A.; Zepp, M.; Mahmood, S.; Ali, D.M.; Berger, M.R.; Adwan, H. CCR5 blockage by maraviroc: A potential therapeutic option for metastatic breast cancer. Cell Oncol. 2019, 42, 93–106. [Google Scholar] [CrossRef] [PubMed]
  23. Toyoma, S.; Suzuki, S.; Kawasaki, Y.; Yamada, T. SDF-1/CXCR4 induces cell invasion through CD147 in squamous cell carcinoma of the hypopharynx. Oncol. Lett. 2020, 20, 1817–1823. [Google Scholar] [CrossRef]
  24. Yoshida, S.; Kawai, H.; Eguchi, T.; Sukegawa, S.; Oo, M.W.; Anqi, C.; Takabatake, K.; Nakano, K.; Okamoto, K.; Nagatsuka, H. Tumor Angiogenic Inhibition Triggered Necrosis (TAITN) in Oral Cancer. Cells 2019, 8, 761. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Taromi, S.; Kayser, G.; Catusse, J.; von Elverfeldt, D.; Reichardt, W.; Braun, F.; Weber, W.A.; Zeiser, R.; Burger, M. CXCR4 antagonists suppress small cell lung cancer progression. Oncotarget 2016, 7, 85185–85195. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Weitzenfeld, P.; Ben-Baruch, A. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett. 2014, 352, 36–53. [Google Scholar] [CrossRef]
  27. Muller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M.E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S.N.; et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410, 50–56. [Google Scholar] [CrossRef]
  28. Chin, A.R.; Wang, S.E. Cancer tills the Premetastatic Field: Mechanistic Basis and Clinical Implications. Clin. Cancer Res. 2016, 22, 3725–3733. [Google Scholar] [CrossRef] [Green Version]
  29. Wang, H.; Pan, J.; Barsky, L.; Jacob, J.C.; Zheng, Y.; Gao, C.; Wang, S.; Zhu, W.; Sun, H.; Lu, L.; et al. Characteristics of pre-metastatic niche: The landscape of molecular and cellular pathways. Mol. Biomed. 2021, 2, 3. [Google Scholar] [CrossRef]
  30. Jiao, X.; Wang, M.; Zhang, Z.; Li, Z.; Ni, D.; Ashton, A.W.; Tang, H.-Y.; Speicher, D.W.; Pestell, R.G. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res. 2021, 23, 11. [Google Scholar] [CrossRef]
  31. Sharma, M.; Afrin, F.; Satija, N.; Tripathi, R.P.; Gangenahalli, G.U. Stromal-Derived Factor-1/CXCR4Signaling: Indispensable Role in Homing and Engraftment of Hematopoietic Stem Cells in Bone Marrow. Stem Cells Dev. 2011, 20, 933–946. [Google Scholar] [CrossRef] [PubMed]
  32. Guo, F.; Wang, Y.; Liu, J.; Mok, S.C.; Xue, F.; Zhang, W. CXCL12/CXCR4: A symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene 2015, 35, 816–826. [Google Scholar] [CrossRef] [PubMed]
  33. Yang, X.; Gao, F.; Zhang, W.; Li, H.; Huang, X.; Wei, J.; Bian, J.; Yang, Y.; Qian, C.; Sun, M. “Star” miR-34a and CXCR4 antagonist based nanoplex for binary cooperative migration treatment against metastatic breast cancer. J. Control. Release 2020, 326, 615–627. [Google Scholar] [CrossRef] [PubMed]
  34. Orimo, A.; Gupta, P.B.; Sgroi, D.C.; Arenzana-Seisdedos, F.; Delaunay, T.; Naeem, R.; Carey, V.J.; Richardson, A.L.; Weinberg, R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121, 335–348. [Google Scholar] [CrossRef] [PubMed]
  35. Dillenburg-Pilla, P.; Patel, V.; Mikelis, C.M.; Zarate-Blades, C.R.; Doci, C.L.; Amornphimoltham, P.; Wang, Z.; Martin, D.; Leelahavanichkul, K.; Dorsam, R.T.; et al. SDF-1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/Galphai/mTORC1 axis. FASEB J. 2015, 29, 1056–1068. [Google Scholar] [CrossRef] [Green Version]
  36. Zhang, F.; Cui, J.Y.; Gao, H.F.; Yu, H.; Gao, F.F.; Chen, J.L.; Chen, L. Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12/CXCR4 axis. Future Oncol. 2020, 16, 2619–2633. [Google Scholar] [CrossRef]
  37. Biasci, D.; Smoragiewicz, M.; Connell, C.M.; Wang, Z.; Gao, Y.; Thaventhiran, J.E.D.; Basu, B.; Magiera, L.; Johnson, T.I.; Bax, L.; et al. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proc. Natl. Acad. Sci. USA 2020, 117, 28960–28970. [Google Scholar] [CrossRef]
  38. Chittasupho, C.; Anuchapreeda, S.; Sarisuta, N. CXCR4 targeted dendrimer for anti-cancer drug delivery and breast cancer cell migration inhibition. Eur. J. Pharm. Biopharm. 2017, 119, 310–321. [Google Scholar] [CrossRef]
  39. Dragoj, M.; Bankovic, J.; Sereti, E.; Stojanov, S.J.; Dimas, K.; Pesic, M.; Stankovic, T. Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors. Investig. New Drugs 2017, 35, 718–732. [Google Scholar] [CrossRef]
  40. Zhou, K.X.; Xie, L.H.; Peng, X.; Guo, Q.M.; Wu, Q.Y.; Wang, W.H.; Zhang, G.L.; Wu, J.F.; Zhang, G.J.; Du, C.W. CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation. Cancer Lett. 2018, 418, 196–203. [Google Scholar] [CrossRef]
  41. Fang, X.; Xie, H.; Duan, H.; Li, P.; Yousaf, M.; Xu, H.; Yang, Y.; Wang, C. Anti-tumor activity of nanomicelles encapsulating CXCR4 peptide antagonist E5. PLoS ONE 2017, 12, e0182697. [Google Scholar] [CrossRef] [PubMed]
  42. He, W.; Yang, T.; Gong, X.H.; Qin, R.Z.; Zhang, X.D.; Liu, W.D. Targeting CXC motif chemokine receptor 4 inhibits the proliferation, migration and angiogenesis of lung cancer cells. Oncol. Lett. 2018, 16, 3976–3982. [Google Scholar] [CrossRef] [PubMed]
  43. Shen, D.; Zhu, L.; Liu, Y.; Peng, Y.; Lan, M.; Fang, K.; Guo, Y. Efficacy evaluation and mechanism study on inhibition of breast cancer cell growth by multimodal targeted nanobubbles carrying AMD070 and ICG. Nanotechnology 2020, 31, 245102. [Google Scholar] [CrossRef]
  44. Uchida, D.; Kuribayashi, N.; Kinouchi, M.; Sawatani, Y.; Shimura, M.; Mori, T.; Hasegawa, T.; Miyamoto, Y.; Kawamata, H. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncol. Rep. 2018, 40, 303–308. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Galsky, M.D.; Vogelzang, N.J.; Conkling, P.; Raddad, E.; Polzer, J.; Roberson, S.; Stille, J.R.; Saleh, M.; Thornton, D. A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer. Clin. Cancer Res. 2014, 20, 3581–3588. [Google Scholar] [CrossRef] [Green Version]
  46. Hainsworth, J.D.; Reeves, J.A.; Mace, J.R.; Crane, E.J.; Hamid, O.; Stille, J.R.; Flynt, A.; Roberson, S.; Polzer, J.; Arrowsmith, E.R. A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC). Target. Oncol. 2016, 11, 643–653. [Google Scholar] [CrossRef]
  47. O’Hara, M.H.; Messersmith, W.; Kindler, H.; Zhang, W.; Pitou, C.; Szpurka, A.M.; Wang, D.; Peng, S.-B.; Vangerow, B.; Khan, A.A.; et al. Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors. J. Pancreat. Cancer 2020, 6, 21–31. [Google Scholar] [CrossRef] [PubMed]
  48. Zhou, J.; Le, K.; Xu, M.; Ming, J.; Yang, W.; Zhang, Q.; Lu, L.; Xi, Z.; Ruan, S.; Huang, T. CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation. Mol. Ther.-Oncolytics 2020, 18, 161–170. [Google Scholar] [CrossRef]
  49. Chaudary, N.; Hill, R.P.; Stulik, L.; Milosevic, M. The Oral CXCR4 Inhibitor X4-136 Improves Tumor Control and Reduces Toxicity in Cervical Cancer Treated with Radiation Therapy and Concurrent Chemotherapy. Int. J. Radiat. Oncol.*Biol.*Phys. 2021, 110, 1317–1324. [Google Scholar] [CrossRef]
  50. Song, J.S.; Chang, C.C.; Wu, C.H.; Dinh, T.K.; Jan, J.J.; Huang, K.W.; Chou, M.C.; Shiue, T.Y.; Yeh, K.C.; Ke, Y.Y.; et al. A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment. Proc. Natl. Acad. Sci. USA 2021, 118, e2015433118. [Google Scholar] [CrossRef]
  51. Dragoj, M.; Milosevic, Z.; Bankovic, J.; Tanic, N.; Pesic, M.; Stankovic, T. Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma. Cell Oncol. 2017, 40, 47–62. [Google Scholar] [CrossRef] [PubMed]
  52. Tang, S.; Hang, Y.; Ding, L.; Tang, W.; Yu, A.; Zhang, C.; Sil, D.; Xie, Y.; Oupicky, D. Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer. Mol. Pharm. 2021, 18, 4448–4458. [Google Scholar] [CrossRef] [PubMed]
  53. Liu, J.-Y.; Chiang, T.; Liu, C.-H.; Chern, G.-G.; Lin, T.-T.; Gao, D.-Y.; Chen, Y. Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer. Mol. Ther. 2015, 23, 1772–1782. [Google Scholar] [CrossRef] [PubMed]
  54. Zhang, F.; Gong, S.; Wu, J.; Li, H.; Oupicky, D.; Sun, M. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy. Biomacromolecules 2017, 18, 1793–1802. [Google Scholar] [CrossRef] [PubMed]
  55. Fang, X.; Zhang, K.; Jiang, M.; Ma, L.; Liu, J.; Xu, H.; Yang, Y.; Wang, C. Enhanced lymphatic delivery of nanomicelles encapsulating CXCR4-recognizing peptide and doxorubicin for the treatment of breast cancer. Int. J. Pharm. 2021, 594, 120183. [Google Scholar] [CrossRef]
  56. Guo, H.; Ge, Y.; Li, X.; Yang, Y.; Meng, J.; Liu, J.; Wang, C.; Xu, H. Targeting the CXCR4/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression. Signal Transduct Target Ther. 2017, 2, 17033. [Google Scholar] [CrossRef] [Green Version]
  57. Li, H.; Chen, Y.; Xu, N.; Yu, M.; Tu, X.; Chen, Z.; Lin, M.; Xie, B.; Fu, J.; Han, L. AMD3100 inhibits brain-specific metastasis in lung cancer via suppressing the SDF-1/CXCR4 axis and protecting blood-brain barrier. Am. J. Transl. Res. 2017, 9, 5259–5274. [Google Scholar]
  58. Reeves, P.M.; Abbaslou, M.A.; Kools, F.R.W.; Poznansky, M.C. CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth. Anticancer Drugs 2017, 28, 935–942. [Google Scholar] [CrossRef]
  59. Santagata, S.; Napolitano, M.; D’Alterio, C.; Desicato, S.; Maro, S.D.; Marinelli, L.; Fragale, A.; Buoncervello, M.; Persico, F.; Gabriele, L.; et al. Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. Oncotarget 2017, 8, 77110–77120. [Google Scholar] [CrossRef] [Green Version]
  60. Izumi, D.; Ishimoto, T.; Miyake, K.; Sugihara, H.; Eto, K.; Sawayama, H.; Yasuda, T.; Kiyozumi, Y.; Kaida, T.; Kurashige, J.; et al. CXCL12/CXCR4 activation by cancer-associated fibroblasts promotes integrin beta1 clustering and invasiveness in gastric cancer. Int. J. Cancer 2016, 138, 1207–1219. [Google Scholar] [CrossRef]
  61. Zhu, W.B.; Zhao, Z.F.; Zhou, X. AMD3100 inhibits epithelial–mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer. J. Cell. Physiol. 2018, 234, 11746–11759. [Google Scholar] [CrossRef] [PubMed]
  62. Morimoto, M.; Matsuo, Y.; Koide, S.; Tsuboi, K.; Shamoto, T.; Sato, T.; Saito, K.; Takahashi, H.; Takeyama, H. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: Effect of CXCR4 antagonists. BMC Cancer 2016, 16, 305. [Google Scholar] [CrossRef] [PubMed]
  63. Li, Z.; Chen, G.; Ding, L.; Wang, Y.; Zhu, C.; Wang, K.; Li, J.; Sun, M.; Oupicky, D. Increased Survival by Pulmonary Treatment of Established Lung Metastases with Dual STAT3/CXCR4 Inhibition by siRNA Nanoemulsions. Mol. Ther. 2019, 27, 2100–2110. [Google Scholar] [CrossRef] [PubMed]
  64. Wang, Y.; Kumar, S.; Rachagani, S.; Sajja, B.R.; Xie, Y.; Hang, Y.; Jain, M.; Li, J.; Boska, M.D.; Batra, S.K.; et al. Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis. Biomaterials 2016, 101, 108–120. [Google Scholar] [CrossRef] [Green Version]
  65. Xie, Y.; Wehrkamp, C.J.; Li, J.; Wang, Y.; Wang, Y.; Mott, J.L.; Oupický, D. Delivery of miR-200c Mimic with Poly(amido amine) CXCR4 Antagonists for Combined Inhibition of Cholangiocarcinoma Cell Invasiveness. Mol. Pharm. 2016, 13, 1073–1080. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Mayr, C.; Neureiter, D.; Pichler, M.; Berr, F.; Wagner, A.; Kiesslich, T.; Namberger, K. Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine. Mol. Med. Rep. 2015, 12, 2247–2252. [Google Scholar] [CrossRef] [Green Version]
  67. Muralidharan, R.; Panneerselvam, J.; Chen, A.; Zhao, Y.D.; Munshi, A.; Ramesh, R. HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer. Cancer Gene Ther. 2015, 22, 581–590. [Google Scholar] [CrossRef] [Green Version]
  68. Xiang, J.; Hurchla, M.A.; Fontana, F.; Su, X.; Amend, S.R.; Esser, A.K.; Douglas, G.J.; Mudalagiriyappa, C.; Luker, K.E.; Pluard, T.; et al. CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer. Mol. Cancer Ther. 2015, 14, 2473–2485. [Google Scholar] [CrossRef] [Green Version]
  69. Huang, M.B.; Giesler, K.E.; Katzman, B.M.; Prosser, A.R.; Truax, V.; Liotta, D.C.; Wilson, L.J.; Bond, V.C. Small molecule CXCR4 antagonists block the HIV-1 Nef/CXCR4 axis and selectively initiate the apoptotic program in breast cancer cells. Oncotarget 2018, 9, 16996–17013. [Google Scholar] [CrossRef] [Green Version]
  70. Mei, L.; Liu, Y.; Zhang, Q.; Gao, H.; Zhang, Z.; He, Q. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin. J. Control. Release 2014, 196, 324–331. [Google Scholar] [CrossRef]
  71. Wong, D.; Kandagatla, P.; Korz, W.; Chinni, S.R. Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis. BMC Urol. 2014, 14, 12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Yang, Q.; Zhang, F.; Ding, Y.; Huang, J.; Chen, S.; Wu, Q.; Wang, Z.; Wang, Z.; Chen, C. Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer. Br. J. Cancer 2014, 110, 1288–1297. [Google Scholar] [CrossRef]
  73. Jeong, W.-J.; Choi, I.J.; Park, M.-W.; An, S.-Y.; Jeon, E.-H.; Paik, J.H.; Sung, M.-W.; Ahn, S.-H. CXCR4 antagonist inhibits perineural invasion of adenoid cystic carcinoma. J. Clin. Pathol. 2014, 67, 992–998. [Google Scholar] [CrossRef] [PubMed]
  74. Heckmann, D.; Maier, P.; Laufs, S.; Wenz, F.; Zeller, W.J.; Fruehauf, S.; Allgayer, H. CXCR4 Expression and Treatment with SDF-1alpha or Plerixafor Modulate Proliferation and Chemosensitivity of Colon Cancer Cells. Transl. Oncol. 2013, 6, 124–132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Greco, S.J.; Patel, S.A.; Bryan, M.; Pliner, L.F.; Banerjee, D.; Rameshwar, P. AMD3100-mediated production of interleukin-1 from mesenchymal stem cells is key to chemosensitivity of breast cancer cells. Am. J. Cancer Res. 2011, 1, 701–715. [Google Scholar]
  76. Portella, L.; Vitale, R.; De Luca, S.; D’Alterio, C.; Ierano, C.; Napolitano, M.; Riccio, A.; Polimeno, M.N.; Monfregola, L.; Barbieri, A.; et al. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS ONE 2013, 8, e74548. [Google Scholar] [CrossRef] [Green Version]
  77. Gong, R.; Ren, H. Targeting chemokines/chemokine receptors: A promising strategy for enhancing the immunotherapy of pancreatic ductal adenocarcinoma. Signal Transduct. Target. Ther. 2020, 5, 149. [Google Scholar] [CrossRef]
  78. Khan, M.A.; Srivastava, S.K.; Zubair, H.; Patel, G.K.; Arora, S.; Khushman, M.; Carter, J.E.; Gorman, G.S.; Singh, S.; Singh, A.P. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer. J. Biol. Chem. 2020, 295, 8413–8424. [Google Scholar] [CrossRef]
  79. Li, Z.; Wang, Y.; Shen, Y.; Qian, C.; Oupicky, D.; Sun, M. Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy. Sci. Adv. 2020, 6, eaaz9240. [Google Scholar] [CrossRef]
  80. Bockorny, B.; Semenisty, V.; Macarulla, T.; Borazanci, E.; Wolpin, B.M.; Stemmer, S.M.; Golan, T.; Geva, R.; Borad, M.J.; Pedersen, K.S.; et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: The COMBAT trial. Nat. Med. 2020, 26, 878–885. [Google Scholar] [CrossRef]
  81. Bockorny, B.; Macarulla, T.; Semenisty, V.; Borazanci, E.; Feliu, J.; Ponz-Sarvise, M.; Abad, D.G.; Oberstein, P.; Alistar, A.; Muñoz, A.; et al. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. Clin. Cancer Res. 2021, 27, 5020–5027. [Google Scholar] [CrossRef]
  82. Choueiri, T.K.; Atkins, M.B.; Rose, T.L.; Alter, R.S.; Ju, Y.; Niland, K.; Wang, Y.; Arbeit, R.; Parasuraman, S.; Gan, L.; et al. A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. Investig. New Drugs 2021, 39, 1019–1027. [Google Scholar] [CrossRef] [PubMed]
  83. Aldinucci, D.; Casagrande, N. Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer. Int. J. Mol. Sci. 2018, 19, 1477. [Google Scholar] [CrossRef] [PubMed]
  84. Ma, G.; Huang, H.; Li, M.; Li, L.; Kong, P.; Zhu, Y.; Xia, T.; Wang, S. Plasma CCL5 promotes EMT-medicated epirubicin-resistance in locally advanced breast cancer. Cancer Biomark 2018, 22, 405–415. [Google Scholar] [CrossRef] [PubMed]
  85. Wang, T.; Wei, Y.; Tian, L.; Song, H.; Ma, Y.; Yao, Q.; Feng, M.; Wang, Y.; Gao, M.; Xue, Y. C-C motif chemokine ligand 5 (CCL5) levels in gastric cancer patient sera predict occult peritoneal metastasis and a poorer prognosis. Int. J. Surg. 2016, 32, 136–142. [Google Scholar] [CrossRef] [PubMed]
  86. Yaal-Hahoshen, N.; Shina, S.; Leider-Trejo, L.; Barnea, I.; Shabtai, E.L.; Azenshtein, E.; Greenberg, I.; Keydar, I.; Ben-Baruch, A. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin. Cancer Res. 2006, 12, 4474–4480. [Google Scholar] [CrossRef] [Green Version]
  87. Suffee, N.; Hlawaty, H.; Meddahi-Pelle, A.; Maillard, L.; Louedec, L.; Haddad, O.; Martin, L.; Laguillier, C.; Richard, B.; Oudar, O.; et al. RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans. Angiogenesis 2012, 15, 727–744. [Google Scholar] [CrossRef]
  88. Zhang, Y.; Yao, F.; Yao, X.; Yi, C.; Tan, C.; Wei, L.; Sun, S. Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncol. Rep. 2009, 21, 1113–1121. [Google Scholar]
  89. Laubli, H.; Spanaus, K.S.; Borsig, L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood 2009, 114, 4583–4591. [Google Scholar] [CrossRef] [Green Version]
  90. Chang, L.-Y.; Lin, Y.-C.; Mahalingam, J.; Huang, C.-T.; Chen, T.-W.; Kang, C.-W.; Peng, H.-M.; Chu, Y.-Y.; Chiang, J.-M.; Dutta, A.; et al. Tumor-Derived Chemokine CCL5 Enhances TGF-β–Mediated Killing of CD8+ T Cells in Colon Cancer by T-Regulatory Cells. Cancer Res. 2012, 72, 1092–1102. [Google Scholar] [CrossRef] [Green Version]
  91. Zhang, Y.; Lv, D.; Kim, H.J.; Kurt, R.A.; Bu, W.; Li, Y.; Ma, X. A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. Cell Res. 2013, 23, 394–408. [Google Scholar] [CrossRef] [PubMed]
  92. Long, H.; Xie, R.; Xiang, T.; Zhao, Z.; Lin, S.; Liang, Z.; Chen, Z.; Zhu, B. Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-kappaB-mediated MMP-9 upregulation. Stem Cells 2012, 30, 2309–2319. [Google Scholar] [CrossRef] [PubMed]
  93. Velasco-Velazquez, M.; Jiao, X.; De La Fuente, M.; Pestell, T.G.; Ertel, A.; Lisanti, M.P.; Pestell, R.G. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 2012, 72, 3839–3850. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Pervaiz, A.; Ansari, S.; Berger, M.R.; Adwan, H. CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells. Med. Oncol. 2015, 32, 158. [Google Scholar] [CrossRef]
  95. Mencarelli, A.; Graziosi, L.; Renga, B.; Cipriani, S.; D’Amore, C.; Francisci, D.; Bruno, A.; Baldelli, F.; Donini, A.; Fiorucci, S. CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination. Transl. Oncol. 2013, 6, 784–793. [Google Scholar] [CrossRef] [Green Version]
  96. Sicoli, D.; Jiao, X.; Ju, X.; Velasco-Velazquez, M.; Ertel, A.; Addya, S.; Li, Z.; Ando, S.; Fatatis, A.; Paudyal, B.; et al. CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines. Cancer Res. 2014, 74, 7103–7114. [Google Scholar] [CrossRef] [Green Version]
  97. Ward, S.T.; Li, K.K.; Hepburn, E.; Weston, C.J.; Curbishley, S.M.; Reynolds, G.M.; Hejmadi, R.K.; Bicknell, R.; Eksteen, B.; Ismail, T.; et al. The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer. Br. J. Cancer 2014, 112, 319–328. [Google Scholar] [CrossRef] [Green Version]
  98. Ochoa-Callejero, L.; Perez-Martinez, L.; Rubio-Mediavilla, S.; Oteo, J.A.; Martinez, A.; Blanco, J.R. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS ONE 2013, 8, e53992. [Google Scholar] [CrossRef]
  99. Tan, M.C.; Goedegebuure, P.S.; Belt, B.A.; Flaherty, B.; Sankpal, N.; Gillanders, W.E.; Eberlein, T.J.; Hsieh, C.S.; Linehan, D.C. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J. Immunol. 2009, 182, 1746–1755. [Google Scholar] [CrossRef] [Green Version]
  100. Wang, J.; Saung, M.T.; Li, K.; Fu, J.; Fujiwara, K.; Niu, N.; Muth, S.; Wang, J.; Xu, Y.; Rozich, N.; et al. CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. J. Exp. Med. 2022, 219, e20211631. [Google Scholar] [CrossRef]
  101. Cambien, B.; Richard-Fiardo, P.; Karimdjee, B.F.; Martini, V.; Ferrua, B.; Pitard, B.; Schmid-Antomarchi, H.; Schmid-Alliana, A. CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRbeta in colorectal carcinoma. PLoS ONE 2011, 6, e28842. [Google Scholar] [CrossRef] [PubMed]
  102. Liu, C.; Yao, Z.; Wang, J.; Zhang, W.; Yang, Y.; Zhang, Y.; Qu, X.; Zhu, Y.; Zou, J.; Peng, S.; et al. Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway. Cell Death Differ. 2019, 27, 1765–1781. [Google Scholar] [CrossRef] [PubMed]
  103. Haag, G.M.; Springfeld, C.; Grün, B.; Apostolidis, L.; Zschäbitz, S.; Dietrich, M.; Berger, A.-K.; Weber, T.F.; Zoernig, I.; Schaaf, M.; et al. Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer—The PICCASSO phase I trial. Eur. J. Cancer 2022, 167, 112–122. [Google Scholar] [CrossRef] [PubMed]
  104. Princen, K.; Hatse, S.; Vermeire, K.; Aquaro, S.; De Clercq, E.; Gerlach, L.O.; Rosenkilde, M.; Schwartz, T.W.; Skerlj, R.; Bridger, G.; et al. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist. J. Virol. 2004, 78, 12996–13006. [Google Scholar] [CrossRef]
  105. Grande, F.; Occhiuzzi, M.A.; Rizzuti, B.; Ioele, G.; De Luca, M.; Tucci, P.; Svicher, V.; Aquaro, S.; Garofalo, A. CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy. Molecules 2019, 24, 550. [Google Scholar] [CrossRef] [Green Version]
  106. Halama, N.; Zoernig, I.; Berthel, A.; Kahlert, C.; Klupp, F.; Suarez-Carmona, M.; Suetterlin, T.; Brand, K.; Krauss, J.; Lasitschka, F.; et al. Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. Cancer Cell 2016, 29, 587–601. [Google Scholar] [CrossRef] [Green Version]
  107. Seo, Y.D.; Jiang, X.; Sullivan, K.M.; Jalikis, F.G.; Smythe, K.S.; Abbasi, A.; Vignali, M.; Park, J.O.; Daniel, S.K.; Pollack, S.M.; et al. Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer. Clin. Cancer Res. 2019, 25, 3934–3945. [Google Scholar] [CrossRef] [Green Version]
  108. Haag, G.M.; Halama, N.; Springfeld, C.; Grün, B.; Apostolidis, L.; Zschaebitz, S.; Dietrich, M.; Berger, A.-K.; Weber, T.F.; Zoernig, I.; et al. Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial. J. Clin. Oncol. 2020, 38, 3010. [Google Scholar] [CrossRef]
Ijms 24 00478 g001 550
Figure 1. Flow diagram of the systematic selection of the studies.
Figure 1. Flow diagram of the systematic selection of the studies.
Ijms 24 00478 g001
Ijms 24 00478 g002 550
Figure 2. Schematic representation of oncogenic mechanisms mediated by the CCR5/CCL5 and the CXCR4/CXCL12 axes in carcinomas. The primary local sources of CCL5 and CXCL12 are CAFs, TILs, cells, macrophages, and tumor cells, while in lymph nodes, the primary sources are lymphatic fibroblasts, endothelial cells, lymphocytes, and tumor cells. These axes have a role in early events, such as epithelial–mesenchymal transition, local immune response modulation, local cell invasion, migration, and lymphangiogenesis, and in late events, such as premetastatic niche preparation, migration to lymph nodes (oncochemotaxis), and lymph node metastasis.
Figure 2. Schematic representation of oncogenic mechanisms mediated by the CCR5/CCL5 and the CXCR4/CXCL12 axes in carcinomas. The primary local sources of CCL5 and CXCL12 are CAFs, TILs, cells, macrophages, and tumor cells, while in lymph nodes, the primary sources are lymphatic fibroblasts, endothelial cells, lymphocytes, and tumor cells. These axes have a role in early events, such as epithelial–mesenchymal transition, local immune response modulation, local cell invasion, migration, and lymphangiogenesis, and in late events, such as premetastatic niche preparation, migration to lymph nodes (oncochemotaxis), and lymph node metastasis.
Ijms 24 00478 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

González-Arriagada, W.A.; García, I.E.; Martínez-Flores, R.; Morales-Pison, S.; Coletta, R.D. Therapeutic Perspectives of HIV-Associated Chemokine Receptor (CCR5 and CXCR4) Antagonists in Carcinomas. Int. J. Mol. Sci. 2023, 24, 478. https://doi.org/10.3390/ijms24010478

AMA Style

González-Arriagada WA, García IE, Martínez-Flores R, Morales-Pison S, Coletta RD. Therapeutic Perspectives of HIV-Associated Chemokine Receptor (CCR5 and CXCR4) Antagonists in Carcinomas. International Journal of Molecular Sciences. 2023; 24(1):478. https://doi.org/10.3390/ijms24010478

Chicago/Turabian Style

González-Arriagada, Wilfredo Alejandro, Isaac E. García, René Martínez-Flores, Sebastián Morales-Pison, and Ricardo D. Coletta. 2023. "Therapeutic Perspectives of HIV-Associated Chemokine Receptor (CCR5 and CXCR4) Antagonists in Carcinomas" International Journal of Molecular Sciences 24, no. 1: 478. https://doi.org/10.3390/ijms24010478

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop